Zai Lab Announces Inclusion Of VYVGART And Other Medicines In China's 2023 National Reimbursement Drug List

Author: Benzinga Newsdesk | December 13, 2023 02:54am

Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))))) today announced that the 2023 National Reimbursement Drug List (NRDL) released by China's National Healthcare Security Administration (NHSA) has been updated to include the following medicines and indications:

• VYVGART® (efgartigimod alfa injection) is included for the first time in the NRDL for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive;
• NUZYRA® (omadacycline) is included for its oral formulation for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI); and
• ZEJULA® (niraparib) is renewed for the maintenance treatment of adult patients with platinum-sensitive, first-line and recurrent ovarian cancer.

Posted In: ZLAB